Versartis Trial in Pre-pubertal Japanese Children With Growth Hormone Deficiency (GHD) to Assess Long-Acting Growth Hormone (Somavaratan, VRS-317)

Inclusion Criteria: * Chronological Age ≥ 3.0 years and ≤ 9.0 years (girls) or ≤ 10.0 years (boys) * Pre-pubertal status * Diagnosis of GHD as documented by two or more GH stimulation test results * Height SD score ≤ -2.0 at screening * Weight for Stature ≥ 10th percentile * IGF-I SD score ≤ -1.0 at screening * Delayed bone age Exclusion Criteria: * Prior treatment with any growth promoting agent * History of, or current, significant disease * Chromosomal aneuploidy, significant gene mutations (other than those that cause GHD) or confirmed diagnosis of a named syndrome * Birth weight and/or birth length less than 5th percentile for gestational age * A diagnosis of Attention Deficit Hyperactivity Disorder * Daily use of anti-inflammatory doses of glucocorticoid * Prior history of leukemia, lymphoma, sarcoma or cancer * Ocular findings suggestive of increased intracranial pressure and/or retinopathy at screening * Significant spinal abnormalities including scoliosis, kyphosis and spina bifida variants * Significant abnormality in screening laboratory studies